 Mild, moderate and normal healthy subjects will receive IK-1001 as a single IV infusion for 3 hours at 1.5 mgkghr. Blood, plasma, urine and exhaled air will be collected from each subject over 48 hours and at follow-up visit Day 7, to evaluate pharmacokinetics of Hydrogen Sulfide H2S exhaled air, IK-1001 blood and thiosulfate in plasma and urine. Severe subjects will receive IK-1001 as a single IV infusion for 3 hours at 1.0 mgkghr. 